[Comment] The long-term benefits of endovascular therapy
About 2 years have passed since the publication of five endovascular thrombectomy trials1–5 with positive findings and three subsequent trials have also reported similar positive results.6–8 In The Lancet Neurology, Antoni Dávalos and colleagues9 now present the 1-year follow-up results of the REVASCAT trial of endovascular thrombectomy for ischaemic stroke.
[In Context] No past, no future: studies in the art and science of memory
For those with a functioning memory, amnesia is a condition that is almost impossible to conceptualise. Try to envisage the erasure of all past autobiographical memory. Remembering reactivates the pattern of neural activity originally generated, and replays the memory with an awareness of the present. Remembering is therefore an act of creative reimagination, and if this act is denied, the future is also unimaginable. Without the ability to remember, how can we place ourselves in the world around us, hold on to an understanding of self, recognise those we love, own any part of what we have experienced, and know who we have become? Memory is intrinsically connected to identity, and to a large extent, is what makes us truly human.
[In Context] Henrik Zetterberg: biomarking neurological disorders
Henrik Zetterberg's steady outlook on life could date back to his tranquil upbringing close to the Gothenburg archipelago in Sweden. His parents inspired his love of nature, which would eventually translate into a love of science and a medical degree. Today, he is Professor of Neurochemistry, senior consultant of clinical chemistry, and head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg (Gothenburg, Sweden), where he is also co-lead of the Clinical Neurochemistry Laboratory with long-time friend Kaj Blennow.
[In Context] Greg Albers: changing the face of the stroke stopwatch
Treatment for stroke is determined by the stopwatch. Missing the few hours that are the window of opportunity between stroke onset and the time of diagnosis make many patients ineligible for reperfusion therapy, because of concerns that treatment might be too risky or ineffective. Greg Albers, Professor of Neurology and Neurological Sciences, and Director of the Stanford Stroke Center (Stanford University, CA, USA) is “trying to show that the stopwatch does not make the most sense”. He says: “we have to tailor treatment to the individual, not because the majority of people don't do well if you treat them within a chosen timeframe.
[In Context] Ammar Al-Chalabi: from complex genetics to acoustic rock
There are many instances when a doctor becomes a leader in their field and wins prestigious awards, but only happened to fall in to their area of expertise by chance—an accident of circumstance. Ammar Al-Chalabi, Professor of Neurology and Complex Disease Genetics at Kings College London KCL; London, UK) is one of these cases. From a young age, Al-Chalabi was intent on practicing medicine, aiming for the heights of the Australian Flying Doctor Service. His resolve was truly tested when he faced rejection from medical school 14 times over three years, before being accepted by Leicester University (Leicester, UK).